International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 3 , Pages 588-594 , 1 July 2002

Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy

  • Young Kwok, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
    • ,
  • Steven J DiBiase, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Steven J. DiBiase, M.D., Department of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene St., Baltimore, MD 21201 USA. Tel: 410-328-2318; Fax: 410-328-5279
    • Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
    • ,
  • Pradip P Amin, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
    • ,
  • Michael Naslund, M.D.

      Affiliations

    • Department of Urology, University of Maryland School of Medicine, Baltimore, MD, USA
    • ,
  • Geoffrey Sklar, M.D.

      Affiliations

    • Department of Urology, University of Maryland School of Medicine, Baltimore, MD, USA
    • ,
  • Stephen C Jacobs, M.D.

      Affiliations

    • Department of Urology, University of Maryland School of Medicine, Baltimore, MD, USA

Received 1 November 2001 ,Revised 25 January 2002 ,Accepted 6 February 2002.

References 

  1. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life (A structured debate). J Urol. 2000;163:1802–1807
  2. Hanks GE, Hanlon AL, Schultheiss TE, et al.  Dose escalation with 3D conformal treatment (Five year outcomes, treatment optimization, and future directions). Int J Radiat Oncol Biol Phys. 1998;41:501–510
  3. Merrick GS, Butler MW, Galbreath RW, et al.  Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:41–48
  4. Grimm P, Blasko J, Sylvester J, et al.  10-Year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  5. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 1996;14:449–453
  6. Martinez AA, Gonzalez JA, Chung AK, et al.  A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000;88:425–432
  7. D’Amico AV, Whittington R, Malkowicz SB, et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  8. Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 2000;47:129–136
  9. Ragde H, Grado GL, Nadir B, et al.  Modern prostate brachytherapy. CA Cancer J Clin. 2000;50:380–393
  10. Blasko JC, Grimm P, Sylvester J, et al.  Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  11. Zelefsky MJ, Leibel SA, Gaudin PB, et al.  Dose escalation with three-dimensional conformal radiation therapy affects outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  12. Hudson R. Brachytherapy treatments increasing among Medicare population. Health Policy Brief, American Urological Association. IX. Hagerstown, MD: Lippincott, Williams & Wilkins; 1999;
  13. Pound CR, Partin AW, Epstein JL, et al.  Prostate specific antigen after anatomic radical retropubic prostatectomy (Patterns of recurrence and cancer control). Urol Clin North Am. 1997;24:395–405
  14. Dattoli M, Wallner K, Sorace R, et al.  Disease-free survival after external beam irradiation and palladium-103 brachytherapy boost for high-risk prostatic carcinoma. J Brachyther Int. 1997;13:347–354
  15. American Joint Commission on Cancer . AJCC cancer staging manual. 5th ed.. Philadelphia: Lippincott; 1998; p. 203–207.
  16. Anderson LL. Seed spacing nomogram for interstitial implants of I-125 seeds. Med Phys. 1976;3:48–51
  17. ASTRO Consensus Statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol. 1958;53:457–459
  19. Yock TI, Thakral HK, Zeitman AL, et al.  The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer. [Abstract] Int J Radiat Oncol Biol Phys. 2000;48:227
  20. Shipley WU, Thames HD, Sandler HM, et al.  Radiation therapy for clinically localized prostate cancer. JAMA. 1999;281:1598–1604
  21. Ragde H, Korb LJ, Elgamal AA, et al.  Modern prostate brachytherapy (Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up). Cancer. 2000;89:135–141
  22. Moul JW, Connelly RR, Lubeck DP, et al.  Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001;166:1322–1327
  23. Dattoli M, Wallner K, True L, et al.  Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:853–856
  24. Potters L, Cha C, Oshinsky G, et al.  Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 1999;5:301–306
  25. Critz FA, Williams WH, Benton JB, et al.  Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000;163:1085–1089
  26. Critz FA, Levinson AK, Williams WH, et al.  Simultaneous radiotherapy for prostate cancer (125I prostate implant followed by external-beam radiation). Cancer J Sci Am. 1998;4:359–363
  27. Partin AW, Kattan MW, Subong EN, et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer (A multi-institutional update). JAMA. 1997;277:1445–1451
  28. Davis BJ, Pisansky TM, Wilson TM, et al.  The radial distance of extraprostatic extension of prostate carcinoma (Implications for prostate brachytherapy). Cancer. 1999;85:2630–2637
  29. Blasko J, Grimm P, Sylvester J, et al.  The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiat Oncol. 2000;57:273–278
  30. Grado GL, Larson TR, Balch CS, et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 1998;42:289–298
  31. Stock RG, Stone NN, Tabert A, et al.  A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  32. Potters L, Cao Y, Calugaru E, et al.  A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  33. Potters L, Torre T, Kattan M, et al.  The role of external radiotherapy and permanent prostate brachytherapy in low and intermediate risk patients with localized prostate cancer. [Abstract] J Urol. 2001;165:324
  34. Lee WR, deGuzman AF, Bare RL, et al.  Postimplant analysis of transperineal interstitial permanent prostate brachytherapy (Evidence for a learning curve in the first year at a single institution). Int J Radiat Oncol Biol Phys. 2000;46:83–88
  35. Valicenti R, Lu J, Pilepich M, et al.  Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18:2740–2746
  36. Zeitlin SI, Sherman J, Raboy A, et al.  High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol. 1998;160:91–95
  37. Brandeis JM, Litwin MS, Burnison CM, et al.  Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 2000;163:851–857
  38. Gelblum DY, Potters L, Ashley R, et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67

PII: S0360-3016(02)02796-7

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 3 , Pages 588-594 , 1 July 2002

Article Tools

* Image Usage & Resolution